{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:05:46Z","timestamp":1772503546538,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>We evaluated the performance of the HemoCue <jats:styled-content style=\"fixed-case\">WBC DIFF<\/jats:styled-content>, a point\u2010of\u2010care device for total and differential white cell count, primarily to test its suitability for the mandatory white blood cell monitoring in clozapine use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Leukocyte count and 5\u2010part differentiation was performed by the point\u2010of\u2010care device and by routine laboratory method in venous <jats:styled-content style=\"fixed-case\">EDTA<\/jats:styled-content>\u2013blood samples from 20 clozapine users, 20 neutropenic patients, and 20 healthy volunteers. From the volunteers, also a capillary sample was drawn. Intra\u2010assay reproducibility and drop\u2010to\u2010drop variation were tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The correlation between both methods in venous samples was <jats:italic>r<\/jats:italic> &gt; 0.95 for leukocyte, neutrophil, and lymphocyte counts. The correlation between point\u2010of\u2010care (capillary sample) and routine (venous sample) methods for these cells was 0.772; 0.817 and 0.798, respectively. Only for leukocyte and neutrophil counts, the intra\u2010assay reproducibility was sufficient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The point\u2010of\u2010care device can be used to <jats:italic>screen<\/jats:italic> for leukocyte and neutrophil counts. Because of the relatively high measurement uncertainty and poor correlation with venous samples, we recommend to repeat the measurement with a venous sample if cell counts are in the lower reference range. In case of clozapine therapy, neutropenia can probably be excluded if high neutrophil counts are found and patients can continue their therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.12561","type":"journal-article","created":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T08:07:09Z","timestamp":1472285229000},"page":"703-709","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of the performance of a point\u2010of\u2010care method for total and differential white blood cell count in clozapine users"],"prefix":"10.1111","volume":"38","author":[{"given":"H. N.","family":"Bui","sequence":"first","affiliation":[{"name":"Atalmedial Medical Diagnostic Centers Hoofddorp The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P. A. M.","family":"Bogers","sequence":"additional","affiliation":[{"name":"Psychiatric Centre Rivierduinen Oegstgeest The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Community Mental Health Mental Health Service North Holland North Heerhugowaard The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Njo","sequence":"additional","affiliation":[{"name":"Saltro Diagnostic Center for Primary Care Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"Herruer","sequence":"additional","affiliation":[{"name":"Atalmedial Medical Diagnostic Centers Hoofddorp The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0920"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.622"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl003"},{"key":"e_1_2_8_5_1","unstructured":"The Netherlands Clozapine Collaboration Group.Guideline for the use of clozapine; version 05\u201002\u20102013.http:\/\/www.clozapinepluswerkgroep.nl\/wp-content\/uploads\/2013\/07\/Guideline-for-the-use-of-clozapine-2013.pdf. Accessed January 21 2016."},{"key":"e_1_2_8_6_1","unstructured":"Food and Drug Administration.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/019758s054lbl.pdf. Accessed January 21 2016"},{"key":"e_1_2_8_7_1","unstructured":"European Medicines Agency.Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001\/83\/EC for Leponex and associated names International Non\u2010Proprietary Name (INN): clozapine: Background information and Annex III.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Leponex\/human_referral_000089.jsp. Accessed January 21 2016"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.KEBE.070415"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.11.022"},{"key":"e_1_2_8_10_1","unstructured":"Desirable Specifications for Total Error Imprecision and Bias derived from intra\u2010 and inter\u2010individual biologic variation.https:\/\/www.westgard.com\/biodatabase1.htm. Accessed January 2014"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000202"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1309\/EK3C7CTDKNVPXVTN"},{"key":"e_1_2_8_13_1","first-page":"140","article-title":"Evaluation of the Hemocue WBC Diff system for point\u2010of\u2010care counting of total and differential white cells in pediatric samples","volume":"38","author":"Russcher H","year":"2013","journal-title":"Ned Tijdschr Klin Chem Labgeneesk"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1L7DKMPCHPEH"},{"key":"e_1_2_8_15_1","first-page":"65","article-title":"Validatie van de HemoCue WBC Diff Analyzer. Abstract annual congress Dutch society for clinical chemistry","volume":"38","author":"Poland D","year":"2013","journal-title":"Nederlands Tijdschrift voor Klinische Chemie"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijlh.12561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijlh.12561","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.12561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:06:11Z","timestamp":1695539171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.12561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,27]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ijlh.12561"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.12561","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,27]]}}}